Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

Exclusion Criteria

• •1. Involvement of the central nervous system (CNS);
• •2. History of malignancies except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix;
• •3. Uncontrolled cardio- and cerebro-vascular disease, blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases
• •4. Left ventricular ejection fraction\<50%
• •5. Laboratory measures meet the following criteria at screening (unless caused by lymphoma):
• •* Neutrophils\<1.5×10\^9/L
• •* Platelets\<75×10\^9/L (Platelets\<50×10\^9/L in case of bone marrow involvement)
• •* ALT or AST is 2 times higher than the upper limits of normal (ULN), AKP and bilirubin are 1.5 times higher than the ULN.
• •* Creatinine is 1.5 times higher than the ULN.
• •6. HIV-infected patients
• •7. Patients with psychiatric disorders or patients who are known or suspected to be unable to fully comply with the study protocol
• •8. Pregnant or lactation
• •9. Require treatment with strong/moderate CYP3A inhibitors or inducers.
• •10. Inability to swallow capsules or presence of diseases that significantly affect gastrointestinal function, such as malabsorption syndrome, post-bariatric surgery, inflammatory bowel disease and complete or incomplete intestinal obstruction
• •11. Other medical conditions determined by the researchers that may affect the study